59 related articles for article (PubMed ID: 38483404)
1. Intravesical oncolytic virotherapy and immunotherapy for non-muscle-invasive bladder cancer mouse model.
Smelser WW; Wang J; Ogden KM; Chang SS; Kirschner AN
BJU Int; 2023 Sep; 132(3):298-306. PubMed ID: 36961272
[TBL] [Abstract][Full Text] [Related]
2. Bacillus Calmette-Guérin immunotherapy induces an efficient antitumor response to control murine melanoma depending on MyD88 signaling.
Borges VM; Marinho FV; Caldeira CVA; de Queiroz NMGP; Oliveira SC
Front Immunol; 2024; 15():1380069. PubMed ID: 38835781
[TBL] [Abstract][Full Text] [Related]
3. E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer.
Cheng C; Varn FS; Marsit CJ
Mol Cancer Res; 2015 Sep; 13(9):1316-24. PubMed ID: 26032289
[TBL] [Abstract][Full Text] [Related]
4. Lactobacillus rhamnosus GG induces tumor regression in mice bearing orthotopic bladder tumors.
Seow SW; Cai S; Rahmat JN; Bay BH; Lee YK; Chan YH; Mahendran R
Cancer Sci; 2010 Mar; 101(3):751-8. PubMed ID: 20015287
[TBL] [Abstract][Full Text] [Related]
5. Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration.
Tyagi P; Hafron J; Kaufman J; Chancellor M
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732167
[TBL] [Abstract][Full Text] [Related]
6. Alendronate modulates cytokine responses in healthy young individuals after BCG vaccination.
Bulut O; Kilic G; Debisarun PA; Röring RJ; Sun S; Kolkman M; van Rijssen E; Ten Oever J; Koenen H; Barreiro L; Domínguez-Andrés J; Netea MG
Immunol Lett; 2024 Jun; 267():106851. PubMed ID: 38479480
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic changes associated with Bacillus Calmette-Guerin (BCG) treatment in bladder cancer.
Picard LC; Rich FJ; Kenwright DN; Stevens AJ
Biochim Biophys Acta Rev Cancer; 2024 May; ():189123. PubMed ID: 38806074
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.
Brown MC; Holl EK; Boczkowski D; Dobrikova E; Mosaheb M; Chandramohan V; Bigner DD; Gromeier M; Nair SK
Sci Transl Med; 2017 Sep; 9(408):. PubMed ID: 28931654
[TBL] [Abstract][Full Text] [Related]
9. Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents.
Obermajer N; Urban J; Wieckowski E; Muthuswamy R; Ravindranathan R; Bartlett DL; Kalinski P
Nat Protoc; 2018 Feb; 13(2):335-357. PubMed ID: 29345636
[TBL] [Abstract][Full Text] [Related]
10. Microbial cancer immunotherapy reprograms hematopoietic stem cells to enhance anti-tumor immunity.
Daman AW; Antonelli AC; Redelman-Sidi G; Paddock L; Cheong JG; Jurado LF; Benjamin A; Jiang S; Ahimovic D; Khayat S; Bale MJ; Loutochin O; McPherson VA; Pe'er D; Divangahi M; Pietzak E; Josefowicz SZ; Glickman M
bioRxiv; 2024 Jun; ():. PubMed ID: 38562703
[TBL] [Abstract][Full Text] [Related]
11. Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations.
Kerzeli IK; Lord M; Doroszko M; Elgendy R; Chourlia A; Stepanek I; Larsson E; van Hooren L; Nelander S; Malmstrom PU; Dragomir A; Segersten U; Mangsbo SM
PLoS One; 2021; 16(7):e0253178. PubMed ID: 34232958
[TBL] [Abstract][Full Text] [Related]
12. Toward improved effectiveness of bladder cancer immunotherapy.
Kalinski P; Gingrich JR
Immunotherapy; 2015; 7(10):1039-42. PubMed ID: 26507359
[No Abstract] [Full Text] [Related]
13. Effects of oral butyrate supplementation on inflammatory potential of circulating peripheral blood mononuclear cells in healthy and obese males.
Cleophas MCP; Ratter JM; Bekkering S; Quintin J; Schraa K; Stroes ES; Netea MG; Joosten LAB
Sci Rep; 2019 Jan; 9(1):775. PubMed ID: 30692581
[TBL] [Abstract][Full Text] [Related]
14. New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.
Ghasemzadeh A; Bivalacqua TJ; Hahn NM; Drake CG
Clin Cancer Res; 2016 Feb; 22(4):793-801. PubMed ID: 26683632
[TBL] [Abstract][Full Text] [Related]
15. Multifactoral immune modulation potentiates durable remission in multiple models of aggressive malignancy.
Halpert MM; Burns BA; Rosario SR; Withers HG; Trivedi AJ; Hofferek CJ; Gephart BD; Wang H; Vazquez-Perez J; Amanya SB; Hyslop ST; Yang J; Kemnade JO; Sandulache VC; Konduri V; Decker WK
FASEB J; 2024 May; 38(10):e23644. PubMed ID: 38738472
[TBL] [Abstract][Full Text] [Related]
16. Trained immunity in atherosclerotic cardiovascular disease.
Riksen NP; Bekkering S; Mulder WJM; Netea MG
Nat Rev Cardiol; 2023 Dec; 20(12):799-811. PubMed ID: 37322182
[TBL] [Abstract][Full Text] [Related]
17. Role of trained innate immunity against mucosal cancer.
Wang T; Wang Y; Zhang J; Yao Y
Curr Opin Virol; 2024 Feb; 64():101387. PubMed ID: 38364654
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Proteomic Changes in Tumor and Immune Organs Reveal Systemic Immune Response to Tumor Development.
Li Z; Liu S; Gao Z; Ji L; Jiao J; Zheng N; Li X; Wang G; Qin J; Wang Y
Mol Cell Proteomics; 2024 May; 23(5):100756. PubMed ID: 38554776
[TBL] [Abstract][Full Text] [Related]
19. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
Atallah A; Grossman A; Nauman RW; Paré JF; Khan A; Siemens DR; Cotechini T; Graham CH
Int J Cancer; 2024 Jul; 155(2):352-364. PubMed ID: 38483404
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
